Supplement contract manufacturing: dose form, ingredient identity and label exposure

The dose form picks the factory

A tablet press, an encapsulator, a gummy depositor, a powder blender and a liquid filler live in separate plants with separate skills, and few sites cover more than a couple convincingly. The choice cascades. Tablets need binders, disintegrants and a compressible blend, restricting how much active will fit. Capsules take less processing but hold less volume. Gummies are a confectionery process where actives degrade in heat and the sugar system dominates the eating experience. Powders sidestep compression and hand the dosing problem to the consumer. Settle the form first, then find the site; the reverse order produces a reformulation.

Ingredient identity is the test that actually matters

Botanical extracts, amino acids and vitamin forms vary enormously in what they really contain, and the same name on two invoices can describe different material. The controls that count are specifications naming the species, the plant part, the extraction ratio, the standardised marker and its acceptable range, together with identity testing on receipt rather than reliance on a supplier's certificate. Ask what the factory tests, what it accepts on paper alone, and whether identity confirmation runs on the specific lots used for your batches. Adulteration in this category is well documented, and the brand carries the consequence of it.

Overage, potency and what the label promises across shelf life

Actives degrade, and a declared figure has to stay true until the end of the stated life. Manufacturers handle this with overage, filling above the declared amount so the product still meets its claim as it ages. How much is added, on what stability evidence, and who decided are questions a brand should be able to answer, because overage costs money on every unit while an inadequate allowance produces an out-of-specification result during a market check. Ask to see the stability data supporting the overage rather than accepting it as established house practice.

Blend uniformity is the quiet failure mode

Where an active sits at a small proportion of the blend, distributing it evenly is genuinely hard. Segregation during handling, static charge, particle size differences and transfers between vessels all conspire to concentrate material in some units while starving others. Content uniformity testing exists precisely for this, and it is the check most likely to be trimmed when a site is under pressure. For any low-dose or high-value active, agree what uniformity testing gets performed, at how many points across the batch, and what happens when a result lands close to the limit.

The regulatory weight sits with the brand

In most markets supplements are not approved before sale, which many new brands read as an absence of rules. What exists instead is a set of obligations falling on whoever markets the product: permitted ingredients and forms, restrictions on what may be said, mandatory warnings, and notification requirements in some jurisdictions. The factory makes what you specify and will not warn you that a claim is unlawful in the country you intend to sell into. Somebody on your side has to own that assessment, market by market, before artwork is committed to print.

Frequently asked questions

Who is responsible if tested potency does not match the label?

The brand, in front of regulators and customers, with a contractual claim against the manufacturer where the batch left their site outside specification. That distinction matters because the remedies differ enormously: the factory's exposure is generally the value of the goods, while yours includes withdrawal, delisting and reputational damage. The protection is dull and effective — an agreed specification with limits, release testing before shipment, and retained samples either party can have tested when a dispute arises.

Can the manufacturer supply us one of their own formulas?

Most hold a catalogue of ready formulations, and adopting one is quick and inexpensive. The trade is that the identical product is available to anyone else who asks, differentiation rests wholly on brand and packaging, and the formula remains theirs, so leaving means beginning again. Where the formulation is genuinely central to the proposition, commission it and settle ownership in writing first. Where it is a commodity vitamin blend, the catalogue is usually the sensible choice.

What documentation should arrive with every batch?

A certificate of analysis tied to the batch identifier, showing the tests performed against your agreed specification with actual results rather than a bare statement of conformity. Alongside it: manufacturing date, assigned expiry, quantity produced, and confirmation that raw material identity was verified. Ask for retained samples to be held across the product's life as well. Brands that file this paperwork without reading it discover during an inspection that it never matched their assumptions.